Attorney's Docket No.: 20381-003US1 / PCT04TL2

AP3 Rec'd PCT/PTO 2 2 JUN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kenichiro Kosai et al.

Art Unit : Unknown

Serial No.: To Be Assigned

Examiner: Unknown

Filed

: Herewith

Title

: DRUG FOR PREVENTING OR TREATING HEART DISEASES COMPRISING CD9

Mail Stop PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the documents listed on the enclosed PTO-1449 form. Also enclosed is a search report issued in the corresponding International Application PCT/JP2004/019774.

Note that to meet the requirement for providing "a concise explanation of the relevance" of all references not in English, one may provide an English-language version of a search report in which the relevance of the cited references is indicated. See the Manual of Patent Examining Procedure, Section 609 A(3). An English translation of foreign language document ABB is not provided, as the above-mentioned search report is in English.

This statement is being filed with the application. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:	y. Rochy Zaw
	Y Rocky Tsao Ph.D., J.D Autorney for Applicants Reg. No. 34,053

Fish & Richardson P.C. Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21362606.doc

CERTIFICATE	OF MAILING BY EXPRESS MAIL
Express Mail Label No	EL 980077076 US
	June 22, 2006
Date of Deposit	

10/584109

Sheet 1 of 2

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 20381-003US1

Application No.

Information Disclosure Statement

Applicant Kenichiro Kosai et al. To Be Assigned

by Applicant (Use several sheets if necessary)

K

Filing Date G

(37 CFR §1.98(b))

Herewith

Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA				,		
	AB.						£
	AC						
	AD						
	AE						
	AF	-		•			
	AG	· - · · · · · · · · · · · · · · · · · ·					
	AH						
	ΑI						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AJ							
	AK							
	AL							
	AM							
	AN	0						

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID Document				
	AO	Berditchevski, F., "Complexes of Tetraspanins with Integrins: More than Meets the Eye", Journal of			
		Cell Science, Vol. 114, pp. 4143-4151, 2001.			
	AP Dominguez-Jimenez, C. et al., "Involvement of α3 Integrin/Tetraspanin Complexes in the				
	AI	Angiogenic Response Induced by Angiotensin II", FASEB Journal, Vol 15, pp. 1457-1459, 2001.			
	AQ	Hashida, H. et al., "Clinical Significance of Transmembrane 4 Superfamily in Colon Cancer",			
	, AQ	British journal of Cancer, Vol. 89, pp. 158-167, 2003			
		Higashiyama, S. et al., "The Membrane Protein CD9/DRAP 27 Potentiates the Juxtacrine Growth			
	AR	Factor Activity of the Membrane-anchored Heparin-binding EGF-like Growth Factor", The journal			
		of Cell Biology, Vol. 128, pp. 929-938, 1995.			
-	AS	Iwamoto, R and Mekada E., "Heparin-binding EGF-like Growth Factor: A Juxtacrine Growth			
L	AS	Factor", Cytokine & Growth Factor Reviews, Vol. 11, pp. 335-344, 2000.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant	•

10/584109

AP3 Rec'd PCT/PTO 22 111N Sheet 2 of 2

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 20381-003US1

To Be Assigned

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Applicant Kenichiro Kosai et al.

Filing Date Herewith **Group Art Unit**

(37 CFR §1.98(b))

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	ΑT	Iwamoto, R. et al., "Heparin-binding EGF-like Growth Factor and ErbB Signaling is Essential for			
	Aı	Heart Function", <i>PNAS</i> , Vol. 100, No. 6, pp. 3221-3226, 2003.			
		Jennings, L. K. et al., "The Activation of Human Platelets Mediated by Anti-human Platelet			
	ΑU	p24/CD9 Monoclonal Antibodies", The Journal of Biological Chemistry, Vol. 265, No. 7, pp. 3815-			
		3822, 1990.			
		Kirkland, G. et al., "Heparin-Binding EGF-Like Growth Factor mRNA Is Upregulated in the Peri-			
	AV	Infarct Region of the Remnant Kidney Model: In Vitro Evidence Suggests a Regulatory Role in			
	•••	Myofibroblast Transformation", Journal of the American Society of Nephrology, Vol. 9, pp. 1464-			
		1473, 1998.			
	AW	Klein-Soyer, C. et al. "CD9 Participates in Endothelial Cell Migration During In Vitro Wound			
		Repair", Arterioscler. Thromb. Vasc Biol., Vol. 20, pp. 360-369, 2000.			
	AX	Maecker, H. T. et al., "The Tetraspanin Superfamily: Molecular Facilitators", <i>The FASEB Journal</i> ,			
		Vol. 11, pp. 428-442, 1997.			
	437	Masellis-Smith, A. et Al., "Anti-CD9 Monoclonal Antibodies Induce Homotypic Adhesion of PRE-			
	AY	B Cell Lines by A Novel Mechanism", <i>The Journal of Immunology</i> , Vol. 144, No. 5, pp. 1607-1613,			
		1990. Miyado, K. et al., "Requirements of CD9 on the Egg Plasma Membrane for fertilization", Science,			
	AZ	vol. 287, pp. 321-324, 2000.			
		Miyagawa, Ji. et al., "Localization of Heparin-binding EGF-like Growth Factor in the Smooth			
	AAA	Muscle Cells and Macrophages of Human Atherosclerotic Plaques", J. Clin. Invest., Vol. 95, pp.			
	ДДД	404-411, 1995.			
		Morimoto, C. et al., "Epidermal Growth Factor: EGF (Heparin-binding EGF-like Growth Factor:			
	ABB	HB-EGF)", Clinical Endocrinology, Vol. 51, No. 12, 1137-1143, 2003.			
		Nakagawa, T. et al., "Amino-terminal Processing of Cell Surface Heparin-binding Epidermal			
	ACC	Growth Factor-like Growth Factor Up-regulates Its Juxtacrine but Not its Paracrine Growth Factor			
:		Activity", The Journal of Biological Chemistry, Vol. 271, No. 48, pp. 30858-30863, 1996.			
		Nakamura, K. et al., "Importance of the Major Extracellular Domain of CD9 and the Epidermal			
	ADD	Growth Factor (EGF)-like Domain of Heparin-binding EGF-like Growth Factor for Up-regulation of			
	ADD	Binding and Activity", The Journal of Biological Chemistry, Vol. 275, No. 24, pp. 18284-18290,			
		2000.			
		Nakamura, Y. et al., "Immunohistochemical Distribution of CD9, Heparin Binding Epidermal			
	AEE	Growth Factor-like Growth Factor, and Integrin α3β1 in Normal Human Tissues", The Journal of			
		Histochemistry & Cytochemistry, Vol. 49, No. 4, pp. 439-444, 2001.			
	AFF	Nakata, A. et al., "Localization of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in			
		Human Coronary Arteries", Circulation, vol. 94, pp. 2778-2786, 1996.			
	400	Nishida, M. et al., "Localization of CD9, an Enhancer Protein for Proheparin-Binding Epidermal			
	AGG	Growth Factor-Like Growth Factor, in Human Atherosclerotic Plaques", Arterioscler Thromb Vasc			
		Biol., Vol 20, pp. 1236-1243, 2000.			
	A LILI	Takemura, T. et al., "Coexpression of CD9 Augments the Ability of Membrane-bound Heparin-			
	AHH	binding Epidermal Growth Factor-like Growth Factor (pro HB-EGF) to Preserve Renal Epihelial			
<u></u>		Cell Viability", Kidney International, Vol. 55, pp. 71-81, 1999.			

Examiner Signature	Date Considered		
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with		
next communication to applicant.			